Pregnancy is associated with a hypercoagulable state. Women requiring anticoagulation need careful attention throughout pregnancy and the post-partum period. The choice of anticoagulant therapy, the degree of monitoring, and the therapeutic target should be modulated by balancing the risks and the benefits to the mother and fetus.
This review will examine strategies for anticoagulation during and after pregnancy, with a focus on women with mechanical heart valves. Development of more standardized monitoring protocols and the use of novel anticoagulant agents will be discussed.
RELEVANT PHYSIOLOGY IN PREGNANCY
RISK OF THROMBOSIS. As pregnancy progresses, the risk of hypercoagulability increases, due to increasing levels of thrombogenic factors VII, VIII, and X; von Willebrand factor; and fibrinogen, and decreases in protein S (2) . The risk is highest in the immediate post-partum period and slowly decreases back to prepregnancy levels by 8 to 12 weeks post-partum (3).
In accordance with these observations, one might expect most thrombotic complications to occur in the post-partum period. However, in women with mechanical heart valves, valve thrombosis often occurs during the first trimester (4) . In contrast, VTE in pregnancy occurs in a more predictable fashion, with the highest risk in the puerperium (5) . Valve thrombosis may occur earlier in pregnancy due to subtherapeutic anticoagulation during transition from VKAs to heparins in the early stages of pregnancy, continuously changing anticoagulant agent pharmacokinetics (particularly LMWH) in pregnancy that lead to underdosing, or other, unidentified homeostatic factors germane to patients with mechanical valves (6) (7) (8) . In addition, some women may discontinue VKAs once a diagnosis of pregnancy is made due to concerns about the teratogenic effects of these agents.
This may occur prior to the initiation of another anticoagulant agent, leading to lapses in anticoagulation.
RISK OF BLEEDING. Delivery poses the greatest risk for bleeding. Women must be transitioned off longacting anticoagulant agents to receive regional anesthesia or undergo Cesarean delivery (4) . The American Society of Regional Anesthesia and Pain Medicine recommends that women have an international normalized ratio (INR) #1.5 or that LMWH is discontinued for at least 12 to 24 h before undergoing lumbar instrumentation (9) . Additionally, VKAs cross the placenta, increasing the risk of fetal bleeding during delivery. Therefore, a delicate balance must be achieved to minimize these risks while protecting the gravida against thrombosis.
DRUG PHARMACODYNAMICS AND PHARMACOKINETICS.
The most significant increases in glomerular filtration rate occur during the second trimester and continue through the post-partum period (10) . Medications that are cleared by the kidney typically require proactive dose-adjustment throughout pregnancy. These adjustments for maternal physiological changes are imperative in the case of mechanical valves. Table 1 summarizes select anticoagulant agents and their implications in pregnancy, with Food and Drug Administration (FDA) pregnancy category classifications. Several decades ago, the FDA established 5 categories to indicate the potential of a drug to cause birth defects if used during pregnancy (Online Table 1 ). The categories are determined by the reliability of documentation and the risk to benefit ratio.
They do not take into account any risks from pharmaceutical agents or their metabolites in breast milk.
Most currently available anticoagulant agents are category B; VKAs are classified as category X for their first-trimester effects, except in the presence of mechanical heart valves, where they are considered category D (11, 12) . However, in December 2014, the During vaginal delivery, use of VKAs is associated with a higher risk of fetal hemorrhage, most dangerously intracranial bleeding (15) . Careful planning of the timing and mode of delivery is critical. Some investigators advocate a planned Cesarean delivery for mothers who take any VKAs (19) . However, the mode of delivery should be guided by obstetric indications with the caveat that women who present in labor fully anticoagulated with VKAs should undergo Cesarean Maternal and fetal factors should be taken into consideration when initiating or maintaining anticoagulation. Anticoagulation needs will change across trimesters and shorter acting agents should be used to decrease risk of bleeding at delivery. While vitamin K antagonists may be the safest choice for preventing thromboembolism, they carry risk of fetal loss, embryopathy, and hemorrhage. IV ¼ intravenous; LMWH ¼ low molecular-weight heparin; MHV ¼ mechanical heart valve; Table 2 ). There are several points worth highlighting with this approach.
Although this strategy minimizes both embryopathy and fetal wastage, the anticoagulant effect of warfarin in the fetus remains high, and it is unclear how long before a planned vaginal delivery warfarin needs to be withheld to eliminate the risk of traumatic intracranial hemorrhage in the fetus (22) . For example, if labor ensues prematurely, a Cesarean delivery might be safer for the fetus but carries a higher risk of bleeding for the mother, in addition to the usual postoperative risks. Although giving vitamin K to reverse warfarin's effect in the mother may seem appropriate, it is unclear whether it would reverse warfarin's effect in the fetus to the same magnitude, and importantly, it could precipitate TEC in the setting of a mechanical valve. Additionally, the risk of fetal loss remains a concern with the use of VKAs throughout pregnancy, irrespective of the dose (15, 16 ).
An alternative anticoagulant strategy is weightbased LMWH. It has superior bioavailability compared with subcutaneous UFH, is dosed twice daily, and does not cross the placenta. LMWH is cleared entirely by the kidneys; thus, fixed, weight-based dosing tends to underperform as the pregnancy advances, due to the increase in glomerular filtration rate (and clearance of LMWH) throughout pregnancy (23) . Thus, as per the current guidelines, when LMWH is used, peak anti-Xa level should be checked 4 to 6 h post-dose, and LMWH carries a low risk of TEC when the levels are kept between 1.0 to 1.2 U/ml (23) (24) (25) .
However, concerningly, thrombotic events still occur in patients who achieve therapeutic peak anti-Xa levels (4). One potential explanation is that peak anti-Xa levels might not be adequate to ascertain therapeutic anticoagulation. In a study of 30 pregnant women receiving LMWH, peak anti-Xa was in an "optimal" therapeutic range of 0.8 to 1.2 U/ml in 115 of 187 of the measurements, and subsequent trough levels were subtherapeutic (<0.6 U/ml) in 66 (57%) of these measurements (26). This study advocates a strategy of monitoring trough levels in pregnant women with mechanical valves, particularly women who are at high risk of TEC.
Two observations are worth discussing. First, LMWH successfully treats and prevents thromboembolism in pregnant women (27) . The additive risk of thrombosis in the setting of mechanical valve is, perhaps, unique and may not be eliminated by close monitoring of LMWH. Warfarin may be more efficacious than LMWH in preventing thrombosis of mechanical heart valves because warfarin targets factor Subcutaneous UFH at therapeutic doses was 1 of the first agents used as an alternative to VKAs.
It carries a high risk of TEC and its use has largely been abandoned, except in developing countries (4).
Intravenous UFH, however, is indicated in women around the time of delivery, due to its rapid onset and clearance.
Dabigatran and the oral direct factor Xa inhibitors are contraindicated for mechanical heart valves.
Their use in pregnancy may be limited, as they also cross the placenta (11).
THROMBOPHILIA AND VTE. Women with thrombophilia or a history of VTE who take anticoagulant agents before pregnancy should continue anticoagulation during pregnancy. Alshawabkeh et al. Because these medications cross the placenta, their safety in pregnancy cannot be substantiated with this level of evidence (4, 20, 21) .
LIMITATIONS IN CURRENT RESEARCH
The current evidence is limited by inherent biases of single-center case series, small sample sizes, and lack of control arms. The majority of studies enroll patients after they present in the first trimester of pregnancy; thus, there is variable capture of exposure time to whatever therapy they were taking prior to pregnancy. This results in inaccurate ascertainment of risk attributable to the anticoagulant agents that are subsequently chosen in the later stages of pregnancy.
Second, the contribution of the underlying heart disease and functional status to maternal and fetal risks in women with mechanical valves has not been explored. In the European Registry on Pregnancy and Heart disease of over 1,300 pregnant women with structural heart disease, pre-pregnancy functional status was found to be the most predictive factor for maternal and fetal complications (35 Therapeutic dose *Adapted with permission from Yarrington et al. (31) . †Antithrombin deficiency; double heterozygous for prothrombin G20210A mutation and factor V Leiden; factor V Leiden homozygous or prothrombin G20210A mutation homozygous. ‡Factor V Leiden heterozygous; prothrombin G20210A heterozygous; protein C or protein S deficiency. §First-degree relative with a history of a thrombotic episode before 50 years of age, or other major thrombotic risk factors (obesity or prolonged immobility).
VTE ¼ venous thromboembolism.
Anticoagulation During Pregnancy of the mother and fetal safety poses a challenging dilemma for clinicians caring for women who require anticoagulation during pregnancy. It is imperative to identify these women pre-pregnancy and provide appropriate pre-conceptual counseling.
This is particularly important for women with mechanical heart valves, who must accept that despite meticulous anticoagulation and strict adherence to guidelines, the risk for valve thrombosis and for maternal and fetal adverse outcomes is still high.
Several investigators have suggested innovative approaches to managing women with mechanical heart valves. De Santo et al. (19) "challenged"
young women referred for valve replacement with
VKAs prior to undergoing valve replacement surgery.
The goal was to determine the dose required to achieve a therapeutic INR as a guide to the decision of whether to place a mechanical or a bioprosthetic valve at the time of cardiac surgery. Women who were able to achieve therapeutic INR using <5 mg warfarin were encouraged to undergo a mechanical valve replacement, and all were in the aortic position.
Conversely, women requiring $5 mg warfarin were advised to undergo bioprosthetic valve placement. 
